|Bid||76.46 x 800|
|Ask||76.49 x 1400|
|Day's Range||76.25 - 77.89|
|52 Week Range||42.08 - 86.30|
|Beta (5Y Monthly)||1.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||83.10|
The first quarter was a breeze as Powell pivoted, and China seemed eager to reach a deal with Trump. Both the S&P 500 and Russell 2000 delivered very strong gains as a result, with the Russell 2000, which is composed of smaller companies, outperforming the large-cap stocks slightly during the first quarter. Unfortunately sentiment shifted […]
It’s hard for the little guys to get noticed sometimes, but often, it’s the little guys that are worth watching. Naturally, this applies to investing, too.Much has been said already about the record-breaking year for the S&P 500. As we reached the final month of the decade, after such a sustained rally, it is getting harder and harder to find true bargains. The top analysts, though, know that further down the market cap ladder, unseen by the casual observer, is where some of the true gems reside, the ones from which investors stand to reap substantial rewards.So, we took out our virtual bargain detector, opened TipRanks’ Stock Screener and looked for 3 stocks with smaller market caps poised for growth, specifically ones the analysts think are set for gains in the months ahead. Let’s take a closer look.International Money Express (IMXI)Remittances are making an increasingly large impact on the economies of many countries, playing a part in their economic growth, and in people’s livelihoods. Overall global remittance is expected to grow 3.7% to $715 billion in 2019. This includes $549 billion to developing nations.One company hoping to get a slice of the growing industry is International Money Express. The Miami based company provides remittance services for select Latin American markets, with strongholds in the two biggest markets - it is the market leader in Guatemala, and the second largest provider in Mexico.Additionally, IMXI has set its sights on new territories, both in Latin America and Africa, as well as expanding in the US and Canada. The company favors a differentiated agent acquisition strategy of handpicking agents with which the local migrant population has a cultural or linguistic affinity over increasing the number of agent locations.Cowen’s George Mihalos thinks the game plan is working well. The 5-star analyst noted, “We believe IMXI deserves a premium valuation relative to its money remittance peers given its superior growth profile and differentiated business model [..] We see IMXI leveraging its differentiated agent strategy to further capture market share in the Latin American remittance corridor, driving sustainable low-mid teens revenue growth. With the shares trading at a discount to slower growing peers such as WU, we see an opportunity for multiple expansion near term.”To this end, Mihalos initiated coverage on IMX stock with an Outperform rating, along with a price target of $17. This conveys the 5-star analyst’s confidence in IMXI’s ability to climb 32% higher in the next 12 months. (To watch Mihalos’ track record, click here)Where does the rest of the Street side on this digital payments platform? It appears mostly bullish, as TipRanks analytics demonstrate IMXI as a Strong Buy. Out of 5 analysts tracked by TipRanks in the last 3 months, 4 are bullish on the stock while 1 remains sidelined. With a return potential of nearly 36%, the stock’s consensus target price stands at $17.50 (See IMXI stock analysis on TipRanks)Exicure (XCUR)With a market cap of $219.6 million, Exicure is the smallest company on our list. The micro-cap biotech focuses on developing drugs for neurology, oncology, and dermatology.Exicure’s unique selling point (USP) is its proprietary spherical nucleic acid (SNA) technology, which can better the delivery and efficiency of current nucleic acid-based therapies. The company is expected to announce its first SNA based neurology candidate before year’s end, and it has indicated it will be a rare indication for which there are few available therapies. In addition, Exicure also recently announced an agreement with Allergan to develop treatments for hair disorders, also based on Exicure’s SNA technology.The pioneering biotech has excited Guggenheim’s Yatin Suneja, who wrote, “We expect XCUR’s SNA platform to attract interest from biopharma companies. We believe that nucleic acid therapeutics are a growing class of products, and the highly adaptive SNA technology could potentially improve the delivery and efficiency of multiple compounds. Therefore, we expect strong interest (as highlighted by a recent collaboration with Allergan) from various biopharma players in partnering with XCUR to leverage this technology.”As a result, Suneja thinks the stock, currently at $2.89, will soon be worth $9.00 a share, and recommends buying it. We are talking about over 200% upside here. (To watch Suneja’s track record, click here)Suneja’s bullish call resonates with the Street. Although only 3 analysts have weighed in with a view on Exicure over the last 3 months, all have rated the biotech pioneer as a Buy, making the Street consensus a Strong Buy. The average target stands at $7.33, below Suneja’s target, but still providing ample upside of 154%. (See Exicure stock analysis on TipRanks)Teladoc (TDOC)The advent of the smartphone has changed the way we interact with the world in every possible way, from shopping, to how we get around, to how we consume culture, amongst many other novelties. One industry going through a smart technological transformation right now is the health industry, with the rise of the telehealth space disrupting traditional doctor-patient conventions.RBC’s Sean Dodge thinks Teledoc is ‘virtually unstoppable,’ noting, “Virtual health is going mainstream. Awareness and comfort with the technology is reaching a tipping point and the breadth of potential use-cases is expanding rapidly. There are more examples of this surfacing across healthcare every day. We are also seeing increasing evidence Virtual First benefit design is beginning to take hold, which adds even more momentum to our outlook. While the rising tide will lift all boats, we believe Teladoc is the best positioned to capitalize on this. It's superior consumer engagement platform, breadth of offerings/clinical capabilities and global reach are all important and durable competitive differentiators. The combination of new member adds, cross-selling and ramping utilization should continue to drive 25%+ organic revenue growth for the next 3+ years..”On the back of the glowing assessment, Dodge initiated coverage on Teladoc stock, with an Outperform rating. The analyst suggests that if everything goes as planned, TDOC will be a $100 stock in the next 12 months, implying nearly 28% return. (To watch Dodge’s track record, click here)To find other good ideas for cannabis stocks trading at fair value or better, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Teladoc Health, Inc. (TDOC) today announced the continued expansion of its clinical services with the addition of Teladoc Nutrition, personalized nutrition counseling combined with specialized care from a registered dietitian. Providing virtual access to nutrition services as part of the Teladoc Health comprehensive continuum of care will further optimize long-term health outcomes and ultimately reduce overall medical costs, particularly for those individuals with existing chronic and complicated health conditions.
Benzinga Pro's Stocks To Watch For Monday Evofem Biosciences (EVFM) - Announced its AMPREVENCE study met the primary and secondary endpoints of “reducing the risk of chlamydia and gonorrhea infection, ...
Teladoc's (TDOC) presence in the growing telehealth industry with many deal wins and international expansion is likely to drive long-term growth.
Market indexes jumped higher early in the session and didn't give back their gains to end the day. While the S&P 500 (SPX), Nasdaq 100 (NDX), and Dow Jones Industrial (DJX) indexes all surged higher, it was the small- and micro-cap indexes that showed the most dramatic movements by far. The chart below shows how iShares' index-tracking ETFs for both the Russell 2000 (IWM) and the Russell Microcap (IWC) closed over 2% higher and posted their highest close in the past six months.
WOONSOCKET, R.I., Nov. 19, 2019 /PRNewswire/ -- CVS Health (CVS) today announced that MinuteClinic, the company's retail medical clinic, has rolled out its video visit offering in the state of New Jersey. People in New Jersey with minor illnesses, minor injuries and skin conditions can now seek care through MinuteClinic Video Visits, a telehealth offering.
WOONSOCKET, R.I., Nov. 19, 2019 /PRNewswire/ -- CVS Health (CVS) today announced that MinuteClinic, the company's retail medical clinic, has rolled out its video visit offering in the state of Illinois. People in Illinois with minor illnesses, minor injuries and skin conditions can now seek care through MinuteClinic Video Visits, a telehealth offering.
Teladoc Health (TDOC), the global leader in virtual care, today announced it has earned two accreditations through ClearHealth Quality Institute’s Telemedicine Accreditation Program (TAP). The company gained independent accreditation for both its Consumer-to-Provider services for acute care needs, as well as its Provider-to-Consumer services, which focus on the ongoing provider/patient relationship when treating specialty and chronic conditions, including mental health. It demonstrated the company’s long-term commitment to deliver the highest caliber of care in the industry, as evidenced by Teladoc Health’s other market-leading initiatives such as establishing the first and only Patient Safety Organization (PSO) for virtual care and research into antibiotic stewardship with USC.
Teladoc Health (TDOC), the global leader in virtual care, has received the highest rating by consumers in the Direct-to-Consumer segment in J.D. Power’s inaugural 2019 U.S. Telehealth Satisfaction Study. Leading to this accomplishment were the company’s top marks in customer service. With a score of 870, nearly 20 points above the category average, Teladoc received the highest rating and outperformed all other direct-to-consumer providers in the study.
PURCHASE, NY, Nov. 05, 2019 -- Teladoc Health, the global leader in virtual care, announces that the company is providing free, 24/7 telehealth visits to those displaced by the.
PURCHASE, NY, Nov. 04, 2019 -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, announced today that Jason Gorevic, chief executive officer, and Mala.
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
The N.Y.C.-based startup claims to be the first-to-market company that brings modern-day recruiting tools to the healthcare space.
Teladoc (TDOC) delivered earnings and revenue surprises of 2.50% and 1.31%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Year-over-year Q3 revenue grows 24% to $138.0 million and total visits increase 45% to 928,000 Year-over-year nine months revenue grows 34% to $396.8 million and total visits.
Teladoc (TDOC) Q3 earning are likely to have benefited from increased membership and visits, and accretive effect of earlier acquisitions.
Teladoc Health (TDOC), the global leader in virtual care, announces the U.S. launch of Teladoc Medical Experts, the first-of-its-kind, broad-based virtual center of excellence for individuals dealing with a wide range of complex and/or costly mental and physical medical needs. With this unique service, a state-licensed doctor works directly with individuals, regardless of their geographic location, to get timely answers regarding accurate diagnoses and treatment plans advice, as well as to navigate seamlessly across the virtual and in-person healthcare landscape. Teladoc Medical Experts is currently available for more than 100,000 members across the U.S. “Given that nearly one in three adults with medical conditions also have a mental health condition, it is important to approach care holistically,” said Lew Levy, MD, chief medical officer, Teladoc Health.